- Home
- EXEL vs DKNG Comparison
EXEL vs DKNG Comparison
Compare EXEL & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | DKNG |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 12.5B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EXEL | DKNG |
|---|---|---|
| Price | $56.10 | $23.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 31 |
| Target Price | ★ $46.50 | $38.10 |
| AVG Volume (30 Days) | 2.5M | ★ 10.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.95 | ★ 99.05 |
| EPS | ★ 0.79 | 0.03 |
| Revenue | $452,477,000.00 | ★ $6,054,525,000.00 |
| Revenue This Year | $13.61 | $15.47 |
| Revenue Next Year | $13.13 | $13.09 |
| P/E Ratio | ★ $70.29 | $810.33 |
| Revenue Growth | N/A | ★ 26.99 |
| 52 Week Low | $33.76 | $20.46 |
| 52 Week High | $57.57 | $48.78 |
Technical Indicators
Market Signals| Indicator | EXEL | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 39.28 |
| Support Level | $40.77 | $23.69 |
| Resistance Level | $57.57 | $24.10 |
| Average True Range (ATR) | 1.41 | 1.04 |
| MACD | -0.17 | -0.26 |
| Stochastic Oscillator | 69.69 | 3.80 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to around 40% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.